Skip to Main Content

Paper Details

Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Clin Cancer Res
12
2020
73-gene panel, APOBEC, APOBEC mutational, BRCA, BRCA1, BRCA1/2, BRCA1/2 Mutations, BRCA1/2 mutations, BRCA2, BRCA2 mutation, COSMIC, CTC, CTC culture, CTCs, MBC, Metastatic Breast Cancer, PARP, Patients, TP53, TP53 mutations, cancer, cancer genes, cfDNA, circulating tumor cells, free, free DNA, metastatic breast cancer, olaparib, patient, patients, triple-negative disease
Author NameAffiliation
Michael S LawrenceBroad Institute of Harvard and MIT
Andrzej NiemierkoMassachusetts General Hospital Cancer Center, Harvard Medical School
Jochen K LennerzMassachusetts General Hospital Cancer Center, Harvard Medical School
Steven J IsakoffMassachusetts General Hospital Cancer Center, Harvard Medical School
Mehmet TonerCenter for Engineering in Medicine, Massachusetts General Hospital
Anthony J IafrateMassachusetts General Hospital Cancer Center, Harvard Medical School
Gad GetzMassachusetts General Hospital Cancer Center, Harvard Medical School
Gad GetzMassachusetts General Hospital Cancer Center, Harvard Medical School
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School
  • 1 - 9

Datasets

Release 1.2